Home
    Disclaimer
    ← Back to 2C-P
    2C-P molecular structure

    2C-P Stats & Data

    Psychedelic Research-chemical
    2cp
    NPS DataHub
    MW259.78
    FormulaC13H22ClNO2
    CAS1359704-27-0
    IUPAC2-(2,5-dimethoxy-4-propylphenyl)ethanamine;hydrochloride
    SMILES[Cl-].CCCc1cc(OC)c(CCN)cc1OC.[H+]
    InChIKeyGTAHFPSNRIBSFT-UHFFFAOYSA-N
    Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic
    Half-Life Unknown in humans (long clinical duration suggests slow clearance and/or prolonged receptor engagement)

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT2B receptor agonist (partial)
    5-HT2C receptor agonist (partial)
    5-HT1A receptor agonist
    TAAR1 agonist (rodents)
    Other
    Dopamine transporter phosphorylation

    Effect Profile

    Curated + 124 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    10103.7
    Headspace Depth×3
    107.32.4
    Auditory Effects×1
    10103.6
    Body Load / Somatic Effects×1
    10105.6
    Catalog Erowid BlueLight
    Based on reports from:
    Effect Index Horrid Body Load Glowing Thoughts — nervewing PiHKAL PiHKAL #36: 2C-P Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 2C-P

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    1-3 hours
    2-4 hours
    4-8 hours
    3-6 hours
    8-48 hours
    Total: 10-20 hours
    Insufflated
    15-45 minutes
    30 minutes - 1.5 hours
    4-8 hours
    3-6 hours
    8-24 hours
    Total: 10-16 hours

    Community Effects

    TripSit
    Positive
    visual enhancement

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans (long clinical duration suggests slow clearance and/or prolonged receptor engagement)
    Addiction Potential
    Not associated with compulsive use; physical dependence is very unlikely. Psychological habituation possible with frequent use or coping‑motivated use.

    Tolerance Decay

    Full tolerance 1d Half tolerance 5d Baseline ~14d

    Typical psychedelic acute tolerance appears within the same day and decays over ~1–2 weeks; cross‑tolerance with other serotonergic psychedelics is expected. Data are based on community guidelines for psychedelics generally; specific 2C‑P pharmacokinetics are not established.

    Cross-Tolerances

    LSD
    50% ●○○
    Psilocybin mushrooms
    50% ●○○
    Mescaline
    50% ●○○
    Other 2C‑x phenethylamines
    60% ●○○

    Experience Report Analysis

    Erowid BlueLight
    85 Reports
    2002–2016 Date Range
    68 With Age Data
    30 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 124 experience reports (85 Erowid + 39 Bluelight)

    124 Reports
    137 Effects Detected
    62 Positive
    54 Adverse
    21 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 62

    Color Enhancement 56.4% 83%
    Music Enhancement 40.3% 86%
    Stimulation 35.5% 79%
    Euphoria 35.4% 85%
    Visual Trails 30.8% 82%
    Empathy 26.6% 80%
    Surface Breathing 25.6% 81%
    Sociability Enhancement 25.6% 80%
    Introspection 25.0% 81%
    Contentment 23.1% 80%
    Tactile Enhancement 22.6% 78%
    Joy 20.5% 83%
    Patterning 20.5% 88%
    Body High 18.6% 82%
    Geometric Imagery 17.9% 87%
    Morphing 17.9% 83%
    Focus Enhancement 16.1% 78%
    Fractal Imagery 15.4% 89%
    Entity Imagery 12.8% 81%
    Peace 12.8% 83%

    Adverse Effects 54

    Body Load 51.3% 78%
    Anxiety 47.6% 83%
    Nausea 39.5% 86%
    Insomnia 30.8% 83%
    Confusion 25.8% 82%
    Fear 23.1% 83%
    Thought Disorganization 17.9% 81%
    Vomiting 15.4% 87%
    Pupil Dilation 13.7% 83%
    Muscle Tension 12.9% 85%
    Headache 12.9% 76%
    Stomach Cramps 12.8% 74%
    Jaw Clenching 12.1% 82%
    Increased Heart Rate 10.6% 70%
    Panic 10.3% 85%
    Tremor 10.3% 81%
    Disrupted Sleep Architecture 10.3% 75%
    Appetite Suppression 8.1% 75%
    Sweating 8.0% 85%
    Thought Loops 7.7% 80%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Strong (n=20)
    Visual Distortions 85.0%
    Color Enhancement 65.0%
    Anxiety 60.0%
    Nausea 60.0%
    Music Enhancement 50.0%
    Empathy 45.0%
    Closed-Eye Visuals 40.0%
    Stimulation 40.0%
    Auditory Effects 40.0%
    Euphoria 35.0%
    Sedation 30.0%
    Confusion 30.0%
    Focus Enhancement 25.0%
    Tactile Enhancement 25.0%
    Dissociation 20.0%

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 85 experience reports.

    Limited tier coverage — most reports fall within the Strong range. Effects at other dose levels may not be represented.

    Oral dose range: 9.0–15.0 mg (median 10.0 mg)
    Effect Strong (n=20)
    visual distortions
    85%
    color enhancement
    65%
    anxiety
    60%
    nausea
    60%
    music enhancement
    50%
    empathy
    45%
    closed-eye visuals
    40%
    stimulation
    40%
    auditory effects
    40%
    euphoria
    35%
    sedation
    30%
    confusion
    30%
    focus enhancement
    25%
    tactile enhancement
    25%
    dissociation
    20%
    pupil dilation
    15%
    hospital
    15%
    memory suppression
    15%
    headache
    15%
    open-eye visuals
    15%

    Showing top 20 of 29 effects

    Dosage Distribution

    Dose distribution from experience reports

    Median: 10.0 mg IQR: 9.0–15.0 mg n=36

    Real-World Dose Distribution

    62K Doses

    From 87 individual dose entries

    Oral (n=51)

    Median: 10.0mg 25th: 8.0mg 75th: 10.5mg 90th: 16.0mg
    mg/kg median: 0.133 mg/kg 75th: 0.183

    Insufflated (n=13)

    Median: 8.0mg 25th: 5.0mg 75th: 10.0mg 90th: 13.4mg
    mg/kg median: 0.126 mg/kg 75th: 0.185

    Rectal (n=7)

    Median: 3.0mg 25th: 2.75mg 75th: 6.0mg 90th: 9.6mg
    mg/kg median: 0.025 mg/kg 75th: 0.08

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Oral

    Median: 0.136 mg/kg IQR: 0.11–0.189 mg/kg n=37

    Insufflated

    Median: 0.126 mg/kg IQR: 0.061–0.159 mg/kg n=7

    Redose Patterns

    Redosing behavior across 61 reports

    13.1% Redosed
    1.2 Avg Doses
    240m Median Interval
    Read full reports on Erowid →

    Legal Status

    Controlled internationally under the UN Convention on Psychotropic Substances 1971.
    Country Status Notes
    Austria 2C-P is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich). In its Schedule II, the further specifying NPSV (Neue-Psychoaktive-Substanzen-Verordnung Österreich) explicitly bans all substituted phenetylamines.
    Canada As of October 31, 2016; 2C-P is a controlled substance (Schedule III) in Canada.
    China As of October 2015 2C-P is a controlled substance in China.
    Denmark In Denmark, 2C-P has been added to the list of Schedule B controlled substances.
    Finland Scheduled in "government decree on psychoactive substances banned from the consumer market".
    Germany 2C-P is an Anlage I controlled drug.
    Japan 2C-P is a controlled substance in Japan effective March 25th, 2015.
    Latvia 2C-P is a Schedule I controlled substance.
    Sweden The Riksdag added 2C-P to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of August 16, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2016:80 listed as 2,5-dimetoxi-4-propylfenetylamin.
    Switzerland 2C-P is a controlled substance specifically named under Verzeichnis E.
    United Kingdom 2C-P is a Class A drug in the UK.
    United States 2C-P was placed into Schedule I (with the DEA Drug Code of 7524) making it illegal to possess, distribute and/or manufacture without a license in the United States by an act of the US Congress on July 9, 2012 when US President Barack Obama signed the Synthetic Drug Abuse Prevention Act of 2012 (SDAPA). The law came into effect on January 4, 2013.

    Harm Reduction

    drugs.wiki

    2C‑P is a highly potent, long‑lasting psychedelic; a small change in dose can cause disproportionately larger effects. The come‑up is often delayed, with some users not reaching clear effects until 3–5 hours; redosing during the come‑up has led to accidental overdosing. Volumetric dosing is strongly advised for accurate sub‑10 mg measurement and to reduce weighing error risk. Compared to 2C‑E, 2C‑P is typically longer in duration and can be more intensely visual with a heavier body load at higher doses. Cardiovascular side‑effects (tachycardia, hypertension, vasoconstriction) and anxiety are reported more often at higher doses or with stimulant combinations; those with cardiovascular disease should avoid. Insufflation has a faster onset but is frequently described as more uncomfortable and physically taxing than oral use. In unregulated markets, powders or pills sold as a '2C' or 'Tusi/pink cocaine' have repeatedly contained no 2C substance and instead mixtures of ketamine/MDMA/stimulants and even traces of fentanyls/benzodiazepines; reagent testing or using a professional drug‑checking service is therefore recommended and avoiding redose is prudent if onset is delayed. U.S. legal status: Schedule I; UK: Class A.

    References

    Data Sources

    Cited References

    Drugs.wiki References

    ← Back to 2C-P